DNase I therapy - PeriNess
Alternative Names: DNase NET Inhibitor - PeriNessLatest Information Update: 20 Dec 2024
Price :
$50 *
At a glance
- Originator PeriNess
- Class Endodeoxyribonucleases; Enzymes; Infertility therapies
- Mechanism of Action Extracellular trap inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Male infertility
Most Recent Events
- 05 Dec 2024 Phase-I clinical trials in Male infertility in Israel (unspecified route), prior to December 2024
- 05 Dec 2024 Pharmacodynamics data from preclinical trials in Male infertility released by PeriNess
- 04 Dec 2024 Preclinical trials in Male infertility in Israel (unspecified route), prior to December 2024